Bajaj Healthcare Gets DCGI Nod for Cenobamate Launch in India

Bajaj Healthcare shares saw an upward trajectory on the BSE today, climbing by 2.21% following a significant regulatory announcement. The company secured approval from the Drugs Controller General of India (DCGI) to manufacture and market Cenobamate API and its tablet forms.

Key Market Metrics

• Current Trading Price: Rs. 334.90
• Percentage Increase: 2.21% (up 7.25 points)
• Previous Closing: Rs. 327.65
• Day’s High: Rs. 341.00
• Shares Traded: 8173

This approval, granted under the Central Drugs Standard Control Organization (CDSCO), positions Bajaj Healthcare as the first company to introduce Cenobamate in the Indian market. The move is a critical milestone, reinforcing the company’s commitment to delivering advanced therapies and expanding its footprint within the Central Nervous System (CNS) segment.

Cenobamate Product Details

• Approved Forms: Cenobamate API and Cenobamate Tablets
• Tablet Strengths: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg
• Regulatory Body: Drugs Controller General of India (DCGI)
• Recommendation Source: Subject Expert Committee (SEC)

Cenobamate is classified as a next-generation antiseizure medication, specifically indicated for the treatment of partial-onset seizures in adults. Clinical studies have consistently demonstrated its effectiveness, showing significant seizure reduction and high rates of seizure freedom among patients with inadequately controlled epilepsy.

Company Performance & Structure

• Market Capitalization: Rs. 1127.36 crore
• 52-Week High: Rs. 516.20 (on 25-Sep-2025)
• 52-Week Low: Rs. 272.45 (on 18-May-2026)
• Promoter Holding: 58.59%
• Institutional Holding: 4.11%
• Non-Institutional Holding: 37.30%

Bajaj Healthcare’s primary business operations focus on the development, manufacturing, and supply of Amino Acids, Nutritional Supplements, and Active Pharmaceutical Ingredients (API). These products cater to the Pharmaceutical, Nutraceuticals, and Food industries.